NCT01877694 - Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions

Bacterial Conjunctivitis

Interventions

DRUG

Auriclosene Solution 0.3%

Ophthalmic solution dispensed as drops onto the eye

DRUG

Auriclosene Vehicle

Ophthalmic Vehicle solution dispensed as drops onto the eye

Trial Locations (21)

22902

Charlottesville

23113

Midlothian

27101

Winston-Salem

28078

Huntersville

30189

Woodstock

33761

Clearwater

35244

Birmingham

45246

Cincinnati

45432

Dayton

47714

Evansville

67114

Newton

75110

Corsicana

78215

San Antonio

84015

Clinton

85032

Phoenix

90706

Bellflower

91204

Glendale

92647

Huntington Beach

92804

Anaheim

99202

Spokane

08889

Whitehouse Station